PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
公司动态 - PureTech公司宣布其药物Deupirfenidone用于治疗特发性肺纤维化获得了美国食品药品监督管理局和欧盟委员会的孤儿药资格认定 [1] 产品研发进展 - 获得孤儿药资格认定的药物为Deupirfenidone [1] - 该药物的目标适应症为特发性肺纤维化 [1]